- Home
- FREY vs RCEL Comparison
FREY vs RCEL Comparison
Compare FREY & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- RCEL
- Stock Information
- Founded
- FREY 2018
- RCEL 2020
- Country
- FREY Luxembourg
- RCEL United States
- Employees
- FREY N/A
- RCEL N/A
- Industry
- FREY Industrial Machinery/Components
- RCEL Medical/Dental Instruments
- Sector
- FREY Miscellaneous
- RCEL Health Care
- Exchange
- FREY Nasdaq
- RCEL Nasdaq
- Market Cap
- FREY 364.9M
- RCEL 308.6M
- IPO Year
- FREY N/A
- RCEL N/A
- Fundamental
- Price
- FREY $2.29
- RCEL $8.73
- Analyst Decision
- FREY
- RCEL Buy
- Analyst Count
- FREY 0
- RCEL 5
- Target Price
- FREY N/A
- RCEL $18.00
- AVG Volume (30 Days)
- FREY 3.9M
- RCEL 251.2K
- Earning Date
- FREY 02-27-2025
- RCEL 02-13-2025
- Dividend Yield
- FREY N/A
- RCEL N/A
- EPS Growth
- FREY N/A
- RCEL N/A
- EPS
- FREY N/A
- RCEL N/A
- Revenue
- FREY N/A
- RCEL $60,040,000.00
- Revenue This Year
- FREY N/A
- RCEL $36.71
- Revenue Next Year
- FREY $414.23
- RCEL $54.48
- P/E Ratio
- FREY N/A
- RCEL N/A
- Revenue Growth
- FREY N/A
- RCEL 32.24
- 52 Week Low
- FREY $0.91
- RCEL $7.51
- 52 Week High
- FREY $3.36
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- FREY 48.23
- RCEL 31.80
- Support Level
- FREY $2.11
- RCEL $8.53
- Resistance Level
- FREY $2.71
- RCEL $9.42
- Average True Range (ATR)
- FREY 0.25
- RCEL 0.65
- MACD
- FREY -0.06
- RCEL -0.39
- Stochastic Oscillator
- FREY 18.95
- RCEL 3.89
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.